ATE510553T1 - Beta-2-glycoprotein 1 als angiogenesehemmer - Google Patents

Beta-2-glycoprotein 1 als angiogenesehemmer

Info

Publication number
ATE510553T1
ATE510553T1 AT03755330T AT03755330T ATE510553T1 AT E510553 T1 ATE510553 T1 AT E510553T1 AT 03755330 T AT03755330 T AT 03755330T AT 03755330 T AT03755330 T AT 03755330T AT E510553 T1 ATE510553 T1 AT E510553T1
Authority
AT
Austria
Prior art keywords
tissue
glycoprotein
beta
angiogenesis inhibitor
β2gp1
Prior art date
Application number
AT03755330T
Other languages
English (en)
Inventor
Alan Schroit
Krishnakumar Balasubramanian
Marya Mccarty
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE510553T1 publication Critical patent/ATE510553T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03755330T 2002-05-17 2003-04-02 Beta-2-glycoprotein 1 als angiogenesehemmer ATE510553T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38121902P 2002-05-17 2002-05-17
PCT/US2003/010188 WO2003099833A2 (en) 2002-05-17 2003-04-02 Beta-2-glycoprotein 1 is an inhibitor of angiogenesis

Publications (1)

Publication Number Publication Date
ATE510553T1 true ATE510553T1 (de) 2011-06-15

Family

ID=29584304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03755330T ATE510553T1 (de) 2002-05-17 2003-04-02 Beta-2-glycoprotein 1 als angiogenesehemmer

Country Status (5)

Country Link
US (3) US7329642B2 (de)
EP (1) EP1515754B1 (de)
AT (1) ATE510553T1 (de)
AU (1) AU2003273176A1 (de)
WO (1) WO2003099833A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE510553T1 (de) * 2002-05-17 2011-06-15 Univ Texas Beta-2-glycoprotein 1 als angiogenesehemmer
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
JP5047783B2 (ja) * 2004-05-13 2012-10-10 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク（セーエヌエールエス） ターゲット存在物をおとり存在物へ結合させるための装置、および該装置を使用する検出方法
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
WO2006086891A1 (en) * 2005-02-18 2006-08-24 National Research Council Of Canada Insulin-like growth factor binding protein-4 compounds and methods for inhibiting angiogenesis and tumor growth in mammalian cells
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
EP2565195B1 (de) 2007-03-29 2015-05-06 Wyeth LLC Peripherer Opioid-Rezeptor sowie Antagonisten und Verwendungen davon
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101143207B (zh) * 2007-08-28 2011-04-27 于德民 天然型、断裂型或第V结构域缺失突变型β2糖蛋白I在制备抑制血管新生药物中的应用
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2012030949A2 (en) * 2010-09-01 2012-03-08 Kansas State University Research Foundation B2-glycoprotein i peptide inhibitors
WO2016036949A1 (en) * 2014-09-03 2016-03-10 The Regents Of The University Of California Methods to determine the distribution profiles of circulating rnas
CN105550461B (zh) * 2015-12-30 2018-10-02 哈尔滨理工大学 一种基于断端微动和血供的骨折愈合仿真系统
WO2017133018A1 (zh) * 2016-02-06 2017-08-10 法玛科技顾问股份有限公司 重组β2-糖蛋白胜肽及其于抗肿瘤的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
US20060025329A1 (en) * 1997-02-06 2006-02-02 Todd Hembrough Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
GB9815505D0 (en) 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
JP2002539174A (ja) 1999-03-17 2002-11-19 エントレメッド インコーポレイテッド 癌および血管新生関連の疾病の治療のためのｌｄｌ様受容体リガンドを使用する組成物および方法
CA2384929C (en) 1999-09-15 2006-12-05 Mogam Biotechnology Research Institute A novel angiogenesis inhibitor
EP1355664A4 (de) 2001-01-04 2005-10-26 Vascular Biogenics Ltd "verfahren, bei denen plaque?assoziierte moleküle verwendet werden sowie zusammensetzungen, die diese enthalten; für die vorbeugung und behandlung von atheriosklerose"
ATE510553T1 (de) * 2002-05-17 2011-06-15 Univ Texas Beta-2-glycoprotein 1 als angiogenesehemmer

Also Published As

Publication number Publication date
US20030219406A1 (en) 2003-11-27
AU2003273176A8 (en) 2003-12-12
WO2003099833A3 (en) 2004-08-26
EP1515754A4 (de) 2007-06-20
EP1515754A2 (de) 2005-03-23
US20100226887A1 (en) 2010-09-09
EP1515754B1 (de) 2011-05-25
US20080131397A1 (en) 2008-06-05
WO2003099833A2 (en) 2003-12-04
US7642234B2 (en) 2010-01-05
US7329642B2 (en) 2008-02-12
AU2003273176A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
ATE510553T1 (de) Beta-2-glycoprotein 1 als angiogenesehemmer
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
TW200621240A (en) Cancer treatments
CO5271702A1 (es) Compuesto anticanceroso y metodo de separacion de enantiomeros utiles para sintetizar dicho compuesto
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
ATE324444T1 (de) Tek-antagonisten
DE60329756D1 (de) Mitotische kinesin-hemmer
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
DK0768885T3 (da) Fremgangsmåde til inhibering af cancermetastase ved oral administration af oplöselig modificeret citruspectin
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
ATE408412T1 (de) Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration
IL146125A0 (en) Novel quinones as disease therapies
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
WO2001032210A3 (en) Compositions for treating atheroma and neoplastic tissue
WO2002080854A3 (en) Compositions and methods for the prevention and treatment of human prostate cancer
WO2020176461A3 (en) Methods and compositions for treating neuroendocrine prostate cancer
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
HK1074175A (en) Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
DE60117783D1 (de) Naphthamidin-urokinasinhibitoren
MXPA02008014A (es) Composiciones inhibidoras de tumores de 1-nitroacridina.
DE60312988D1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
WO2004044226A3 (en) Induction of cellular senescence by cdk4 disruption for tumor supression and regression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties